ArticleScientific reports2025
Predictive modeling of flavonoid efficacy against esophageal carcinoma: a comprehensive approach.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal carcinoma poses a significant health challenge, particularly due to its notably high prevalence in East Asia, which underscores the urgent need for innovative treatment strategies. Natural flavonoids are polyphenolic compounds with significant potential to interact with cancer cell pathways; however, their therapeutic application remains constrained by the lack of comprehensive data and consistent experimental evidence. The current study aims to present a comprehensive framework for evaluating the anticancer potential of natural flavonoids, including seven flavones-luteolin, apigenin, chrysin, acacetin, cirsiliol, baicalein and eupatilin-and six flavonols-kaempferol, quercetin, galangin, myricetin, casticin, and gossyptin-against human esophageal carcinoma cells. Extensive experimental data from twenty-two research studies focusing on natural flavonoids and esophageal carcinoma cells were extracted based on specific inclusion criteria that emphasized dose, time, and cell viability. Seven machine learning models-K-Nearest Neighbors, Support Vector Machine, Logistic Regression, Decision Tree (DT), Random Forest, AdaBoost and XGBoost-were employed to predict the optimal dose and time required for flavonoids to achieve 50% cancer cell viability. Hyperparameters were fine-tuned for each algorithm, followed by 5-fold cross-validation on the train dataset to identify the most accurate predictive model. The performance of each algorithm was validated through rigorous hyperparameter optimization and validation on an independent test dataset. The DT model was identified as the most accurate predictor, leading to the development of a simplified model with low complexity that achieved an accuracy of 87.38%. This reliable model enables prediction of effective dosing parameters across diverse esophageal carcinoma cell lines. In conclusion, present study offers a robust yet accessible predictive tool for optimizing treatment strategies against esophageal carcinoma. By combining machine learning with natural compound research, this work exemplifies a transformative approach in oncology, accelerating the development of effective cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.